Dr. Siegel on the PX-171-003-A1 Carfilzomib Study
David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, explains a clinical trial that looked at the newly approved agent carfilzomib.
David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, explains a phase IIb study that enrolled 266 heavily pretreated patients with multiple myeloma who were refractory/ intolerant to bortezomib and at least one immunomodulator, or disease-refractory to all five approved classes of treatment. Of these, 257 were evaluable for response and 266 for safety. Patients could receive up to 12 cycles of carfilzomib.
For the entire population, duration of response was a median of 7.8 months. Additionally, less peripheral neuropathy was observed in the patients receiving carfilzomib.
The FDA approved carfilzomib (Kyprolis) for patients with multiple myeloma who received at least two prior lines of therapy, on July 20, 2012.
